PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma
PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

Combined BRAF and MEK (BRAF/MEK) targeted therapy and programmed cell death protein 1 (PD-1) inhibition improved overall survival in treatment-naïve patients with advanced melanoma compared with other treatments, but the safety profile of PD-1 inhibitors supports using these agents as first-line therapy in these patients, according to a study published in JAMA Oncology.1

Early stage melanoma is cured with surgery in most patients; however, the disease is often in its late stages at diagnosis. These patients are not candidates for surgery, so drug therapy is the main treatment.

Approximately 40% to 60% of melanomas have a mutation in the BRAF protein, with both targeted therapies and immunotherapies available as treatment options; however, which is the optimal first-line treatment is unclear. Therefore, researchers sought to estimate the efficacy and safety of systemic therapies in treatment-naïve patients with advanced BRAF-mutated melanoma.

For the study, researchers conducted a literature search for trials published between 2011 and 2015 in which at least 1 intervention was a targeted (BRAF or MEK) treatment or an immune checkpoint (CTLA-4 or PD-1) inhibitor.

Their search identified 16 eligible articles reporting 15 randomized controlled trials involving 6662 patients assigned to 1 of 10 treatment strategies.

Overall survival was equally improved with both BRAF/MEK targeted therapy and PD-1 immunotherapy compared with all other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor, but no significant difference was seen between BRAF/MEK and PD-1 (HR, 1.02; 95% credible interval [CrI], 0.72-1.45).

Progression-free survival was significantly more improved with BRAF/MEK targeted therapy compared with all other treatments.

Higher objective response rate was associated with BRAF/MEK (OR, 2.00; 95% CrI, 1.64-2.45) vs BRAF alone. Both treatments were better in achieving objective response rates compared with other treatments.

Risk of serious adverse events was associated with chemotherapy and PD-1 inhibition, with no significant difference in risk between the 2 treatment options.

On the basis of these results, although BRAF/MEK and PD-1 inhibition significantly improved overall survival, the safety profile of PD-1 inhibitors advocates use of these agents as first-line therapy in cases in which a rapid response is not a necessity.

Reference

1. Devji T, Levine O, Neupane B. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: a systematic review and network meta-analysis of randomized clinical trials. JAMA Oncol. 2016 Oct 27. doi: 10.1001/jamaoncol.2016.4877. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs